Jun 11, 2019 / 12:00PM GMT
Operator
Good day, ladies and gentlemen, and welcome to the CymaBay 12-week Phase 2b NASH Study webcast and conference call. (Operator Instructions) Please be advised that the call will be recorded at the company's request. It is also being webcast live on the Investors section at the CymaBay website at www.cymabay.com.
Now I would like to turn the call over to your host, Mr. Paul Quinlan, General Counsel at CymaBay. Mr. Quinlan, you may now begin.
Paul T. Quinlan - CymaBay Therapeutics, Inc. - General Counsel & Corporate Secretary
Thank you, operator. This morning, we issued a press release highlighting 12-week top line results from our ongoing 52-week Phase 2b study of seladelpar in patients with nonalcoholic steatohepatitis, or NASH. You can access that release, in addition to the slides that we will be going over on today's call, on our website under the Investors tab.
Joining me today on the call are Sujal Shah, Chief Executive Officer; Dr. Pol Boudes, Chief Medical Officer; Dr.
CymaBay Therapeutics, Inc. Conference Call to Discuss Topline 12-Week Data from an Ongoing Phase 2b Study of Seladelpar in Patients with Nonalcoholic Steatohepatitis Transcript
Jun 11, 2019
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers